FDA Rejects Nasal Spray For Severe Allergic Reactions—Delaying First Needle-Free EpiPen Alternative
ARS Pharmaceuticals chief executive Richard Lowenthal said the company is “very surprised” and “deeply disappointed” by the FDA’s decision.
ARS Pharmaceuticals chief executive Richard Lowenthal said the company is “very surprised” and “deeply disappointed” by the FDA’s decision.
What's Your Reaction?
